The association of telomere length with paternal history of premature myocardial infarction in the European Atherosclerosis Research Study II by Salpea, Klelia D. et al.
ORIGINAL ARTICLE
The association of telomere length with paternal history
of premature myocardial infarction in the European
Atherosclerosis Research Study II
Klelia D. Salpea & Viviane Nicaud & Laurence Tiret &
Philippa J. Talmud & Steve E. Humphries &
on behalf of the EARS II group
Received: 16 November 2007 /Revised: 5 February 2008 /Accepted: 22 February 2008 / Published online: 15 April 2008
# Springer-Verlag 2008
Abstract Inter-individual variability in telomere length is
highly heritable and has been correlated with risk of
coronary heart disease (CHD). Our aim was to determine
the association of mean leukocyte telomere length with
paternal history of premature myocardial infarction (MI).
Mean leukocyte telomere length was measured with real-
time polymerase chain reactions in 369 male students (18–
28 years) with a paternal history of MI before the age of 55,
recruited from 14 European universities, serving as cases
and 396 age-matched controls with no paternal history of
CHD. Overall, cases had borderline significantly shorter
mean length (~550 bp), adjusted for age and geographical
region, than controls (p=0.05). A significant difference in
telomere length across the geographical regions of Europe
was observed (p<0.0001), with shorter mean length in the
Baltic and South and the longest in the Middle. The case–
control difference (∼2.24 kb) in mean length was highly
significant only in the Baltic region (p<0.0001). There is
suggestive evidence that, in young men, the biological
expression of a paternal history of premature MI is at least
in part mediated through inherited short telomeres. The
association with paternal history of MI is strongly seen only
in the Baltic compared to the rest of Europe, but this is not
explained by shorter telomere length in this region.
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Introduction
Despite the significant advances in identifying risk factors
for coronary heart disease (CHD), these do not completely
explain the inter-individual variability related to predispo-
sition for premature disease. Since CHD risk is age-related,
there is a need for a marker of biological age in evaluating
the risk for early onset of CHD and recent studies have
suggested telomere shortening to serve as such [1, 2].
Telomeres are specialized DNA-protein structures at the
end of all chromosomes, which preserve chromosome
stability and integrity. In humans they consist of thousand
tandem repeats of the TTAGGG sequence [3]. Telomere
attrition during mitosis is thought to be a mechanism for
cell senescence, which is induced when the mean length
reduces below a critical value [4]. Thus telomere length
indicates the replicative capacity and biological age of
somatic cells [1].
Vascular endothelial and smooth muscle cell senescence
and consequent dysfunction are key steps in atherogenesis
[2, 5]. Marked telomere shortening has been detected in
senescent vascular cells for human atherosclerotic plaques
[6] and there is a growing evidence of an association
between telomere length and CHD [7]. Leukocyte mean
telomere length (age- and sex-adjusted) of CHD patients
was ∼300 base pairs (bp) shorter than that of healthy
subjects, and this difference was not accounted for by other
CHD risk factors in a study of 203 cases and 180 controls.
In the same study, the risk of myocardial infarction (MI) for
subjects in the lowest quartile of leukocyte telomere length
was ∼3 times higher compared with subjects in the highest
quartile [8]. Telomere length evaluation in the prospective
West of Scotland Primary Prevention Study (WOSCOPS)
with 484 CHD patients and 1,058 controls revealed that
individuals in the middle and the lowest tertiles of
leukocyte telomere length were at higher risk of developing
a CHD event than those in the highest tertile [9]. Telomere
attrition may be a primary abnormality that renders the
organism more susceptible to CHD. However, reduced
leukocyte length in CHD patients may also be a conse-
quence of increased cell turnover induced by chronic
inflammatory response underlying atherogenesis [7]o r
faster shortening due to oxidative stress caused by CHD
risk factors [10].
The consistent average length differences between
species and chromosome arm differences within species
indicate that mean telomere length is genetically deter-
mined [11]. Evidence supporting this derives from a twin
study showing that 78% of mean length variability at an
individual level is inherited [12] and from linkage studies
identifying genetic loci for its determination [13, 14]. In
addition, Graakjaer et al. [15] demonstrated that telomeres
retain the characteristic relative length they had at the outset
of life towards the end of it and that any length alteration
during the lifespan impacts equally on genetically identical
chromosomes. This may imply that the observed decrease
in telomere length of CHD patients can at least be partly
attributed to shorter lengths at birth in those predisposed to
premature onset of CHD.
Our hypothesis is that shorter leukocyte telomere length
is associated with paternal history of premature MI in
individuals of the same age. In the present study we
evaluate this association, and whether it is independent of
classical risk factors, across Europe.
Materials and methods
Subjects
Subjects were participants of European Atherosclerosis
Research Study II (EARS II), which was carried out in
1993. Male students between the ages of 18 and 28 years
whose fathers had proven MI before the age of 55 (cases,
n=407) and age-matched male controls (n=415) were
recruited from 14 university student populations from 11
European countries: Tallinn in Estonia (cases/controls, 32/
36), Helsinki (32/33), and Oulu (23/23) in Finland were
designated Baltic; Glasgow (31/31), Belfast (33/33), and
Bristol (22/23) were designated United Kingdom (UK);
Aarhus in Denmark (30/30), Hamburg in Germany (32/32),
Ghent in Belgium (32/32), and Zurich in Switzerland (36/
36) were designated Middle Europe; Lisbon in Portugal
(18/18), Reus in Spain (30/33), Naples in Italy (30/30), and
Athens in Greece (26/25) were designated South Europe.
The subjects were presumed to have been born in the
country where they were studying. Details of lifestyle, i.e.,
smoking, alcohol consumption, medication and physical
activity, personal and family medical history, and physio-
logical measurements [i.e., height, weight, blood pressure
(BP), and waist and hip circumferences] were established
using standardized questionnaires and protocols (Table 1).
Body mass index was calculated as weight/height
2. The
study has been approved by ethics committees of collabo-
rating centers and the subjects have given informed
consent.
Biochemical measurements
Blood samples were handled according to specified
instructions and were sent to Nancy (France) for storage.
They were then dispatched to the different laboratories for
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done in dry ice. All fasting lipids, apolipoproteins (apo),
glucose, and insulin were measured after 12-h overnight
fasting. Plasma total cholesterol, high-density lipoprotein
(HDL) cholesterol and triglycerides were measured in
Glasgow, UK according to the Lipid Research Clinics
Manual of Laboratory Operations standardized to the
Centres for Disease Control, Atlanta, GA, USA. Low-
density lipoprotein cholesterol was calculated using the
Friedewald formula. The apo A-I, B, and E levels
measurement was performed in Brugge, Belgium according
to methods previously described [16, 17]. Blood glucose
was measured after protein removal by glucose dehydro-
genase method and insulin level by radioimmunoassay. The
reliability of laboratory performance was assessed by
undertaking a repeat blinded analysis of one blood sample
in every 20. The correlation between the repeated measure-
ments was r>0.95.
Leukocyte telomere length measurement
Leukocyte DNA, extracted by the salting-out method [18],
was available for 774 samples. Telomere length was
measured in these DNA samples using a quantitative
polymerase chain reaction (PCR)-based method [19]. The
relative telomere length was calculated as the ratio of
telomere repeats to single-copy gene (SCG) copies (T/S
ratio). For each sample the quantity of telomere repeats and
the quantity of SCG copies were determined in comparison
to a reference sample in a telomere and a SCG quantitative
PCR, respectively. All PCRs were performed on the Rotor-
Gene 6000 (Corbett Research Ltd, Cambridge, UK).
The raw data from each PCR were analysed using the
comparative quantification analysis (Rotor-Gene 6000
software, Corbett Research Ltd, Cambridge, UK). The
second derivative of the amplification curve was considered
in order to identify the peak of the exponential amplifica-
tion and determine the Take-Off of the reaction. The Take-
Off was estimated by finding the first point to be 80%
below the peak level. Based on the Take-Off point and the
amplification, the method calculated the relative quantity of
telomere repeats or SCG copies in each sample compared to
the reference sample. The same reference DNA was used in
all runs to allow comparison of the results in different runs.
Every sample was run in duplicate and the mean data were
used for the calculations.
The acidic ribosomal phosphoprotein PO (36B4) gene
was chosen as SCG. The primers used for the telomere and
the SCG amplification were as in Cawthon's report [19]
(telomere forward: GGTTTTTGAGGGTGAGGGTGAGG
GTGAGGGTGAGGGT/telomere reverse: TCCCGACTAT
CCCTATCCCTATCCCTATCCCTATCCCTA) (SCG for-
ward: CAGCAAGTGGGAAGGTGTAATCC/SCG reverse:
CCCATTCTATCATCAACGGGTACAA). In the telomere
Table 1 Characteristics at recruitment in cases and controls
Cases (n=369) Controls (n=396) p values
Age (years) 22.7 (0.1) 22.7 (0.1) 0.92
BMI (kg/m
2) 23.4 (0.1) 23.3 (0.1) 0.64
Waist/hip ratio 0.852 (0.002) 0.852 (0.002) 0.99
SBP (mmHg) 117.4 (0.5) 117.4 (0.5) 0.95
DBP (mmHg) 73.3 (0.5) 73.1 (0.5) 0.75
Total cholesterol (mmol/l) 4.53 (0.04) 4.30 (0.04) 0.0001
HDL (mmol/l) 1.19 (0.01) 1.19 (0.01) 0.98
Apo A1 (mg/dl) 100.1 (0.9) 100.7 (0.9) 0.61
Apo B (mg/dl) 73.6 (0.9) 69.0 (0.8) 0.0002
Apo E (mg/dl) 2.90 (0.05) 2.78 (0.05) 0.07
Triglycerides (mmol/l)
a 0.91 (0.88–0.95) 0.91 (0.87–0.94)) 0.72
Glucose (mmol/l) 5.16 (0.02) 5.17 (0.02) 0.53
Insulin (mU/l) 10.1 (0.2) 10.6 (0.2) 0.15
Homocysteine (μmol/l)
b 10.15 (9.82–10.49) 10.31 (9.98–10.64) 0.50
Alcohol consumption above median (>8 g/day) (%) 46.9% 42.2% 0.19
Smokers (%) 26.4% 25.6% 0.80
Physical activity (%)
Low 9.9% 8.4%
Moderate 72.3% 76.3% 0.78
Heavy 14.8% 15.3%
Means (standard error) are adjusted for age and region
BMI Body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HDL high density lipoprotein, Apo apolipoprotein
a,bTriglyceride and homocysteine were log-transformed for tests; geometric means (95% CI) are presented
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reverse) and the cycling profile: 95°C incubation for
10 min, followed by 22 cycles of 95°C for 15 s and 58°C
for 120 s. In the SCG PCR, primer concentrations were
300/500 nM and the cycling profile: 95°C incubation for
10 min, followed by 30 cycles of 95°C for 15 s and 58°C
for 60 s. For both the telomere and the SCG PCR the final
reaction volume was 25 μl consisting of 1× SYBR Green,
1× qPCR mix (2× SensiMix NoRef DNA kit, Quantace,
London, UK), 30 ng of template, and the respective primer
concentrations. In each run of 32 samples, a reference
sample and a no-template control, all in duplicate, were
included. The specificity of all amplifications was deter-
mined by melting curve analysis. All analyses were
processed blinded to case–control status of samples.
A dilution series (1.25 ng/μl–160 ng/μl, twofold
dilution, eight points) was run after optimization for both
the telomere and SCG PCRs. For both assays, linearity
(R
2>0.98) over this range of input DNA and efficiency
over 91% was observed (web appendix 1 and 2). Nine
samples fell outside the range defined by the standard
curves and were excluded.
In order to test the reproducibility of the method, 10
randomly chosen samples were run in duplicates on two
consecutive days. There was a significant linearity between
the measurements obtained on the two different days in linear
regression analysis (R
2=0.79, p=0.001, web appendix 3).
Moreover, the reproducibility was also assessed with Spear-
man's non-parametric test of pair-wise correlation that looks
at the ranking of each sample. The correlation of the lengths'
r a n k i n ga sm e a s u r e do nt h et w od i f f e r e n td a y sw a s
significant (Spearman coefficient=0.82, p=0.004). The
coefficient of variation of the T/S ratios in the repeated
measurements of the same sample was 5.6%.
To validate the assay, 32 DNA samples of subjects aged
24 to 54 years from the Cardiovascular Sciences Depart-
ment, Leicester University DNA bank were measured in
duplicate with the quantitative PCR method in our
laboratory. These were then compared to measurements
obtained by the conventional terminal restriction fragment
(TRF) analysis in Leicester University, as previously
described [2]. A significant positive correlation between
the telomere length measurements obtained with the two
different methods was found by linear regression analysis
(R
2=0.61, p<0.0001, web appendix 4). A certain deviation
from the length calculated with TRF analysis was expected,
since TRF analysis also measures the highly variable sub-
telomeric region, in contrast to the PCR-based method.
Statistical analysis
Statistical analysis was performed using the SAS statistical
software (version 9.1). The differences in the clinical
characteristics between cases and controls were tested by
a chi
2 test, for lifestyle factors which were categorical, and
by a general linear model adjusted for age and region, for
continuous phenotypes. The mean telomere length (T/S
ratios), triglycerides and homocysteine were not normally
distributed (positive skewness), and thus log-transformed
data were used for tests and correlations, while geometric
means (95% CI) are presented in the tables. Differences in
telomere length between European regions were tested by a
general linear model adjusted for age and case–control
status. Differences between cases and controls in telomere
length were calculated by a general linear model adjusted
for age and region. Homogeneity of the case–control
difference across regions was tested by introducing the
corresponding interaction term in the general linear model.
Partial Pearson's correlation coefficients between telomere
length and continuous classical CHD risk factors, calculat-
ed separately in cases and controls, were adjusted for age
and region. For this purpose, region was introduced as three
dummy variates. Homogeneity of the associations in cases
and controls was tested by use of a general linear model
where the interaction term: “status X telomere length”, was
introduced. Since all interactions were non-significant,
cases and controls were pooled to calculate partial Pearson's
correlation coefficients further adjusted for case–control
status. The association between telomere length and
categorical lifestyle factors (physical activity, alcohol and
tobacco consumption) were calculated separately in cases
and controls by a general linear model adjusted for age and
region. After having verified that there was no interaction
between status and categorical factors, cases and controls
were pooled to calculate the overall associations further
adjusted for case–control status.
Results
Study cohort
Leukocyte mean telomere length was successfully deter-
mined in 369 cases and 396 controls. The cases and the
controls did not differ significantly in any physiological or
lifestyle characteristics. Total cholesterol and apo B levels
were higher in cases than in controls. No significant
differences were found in the other biochemical measure-
ments (Table 1).
Geographical differences
There was a significant difference in mean telomere length
across the geographical regions of Europe after adjustment
for age and paternal history of MI (p<0.0001). Shorter
818 J Mol Med (2008) 86:815–824mean length was found in the Baltic (1.18 [1.08–1.30]) and
South (1.11 [1.02–1.21]) regions and the longest in the
Middle of Europe (1.69 [1.56–1.84]) (Table 2, Fig. 1).
Case–control differences
Overall, cases had borderline significantly shorter mean
length than controls after adjusting for age and region (1.30
[1.22–1.39] vs. 1.42 [1.34–1.52], p=0.05) (Table 2). Using
the regression line shown in web appendix 4, this difference
corresponds to 550 bp approximately. When considering
each geographical region separately, only in the Baltic
mean telomere length was significantly shorter (∼2.24 kb)
in cases compared to controls (0.96 [0.84–1.09] vs. 1.45
[1.27–1.65], p<0.0001) (Table 2).
We categorized the length in region-specific quintiles, in
order to illustrate the length's distribution and minimize
misclassification. It appeared that the greater difference
between the percentages of cases and controls was seen in
the lowest quintile of length in the Baltic region (Fig. 2).
Association of mean telomere length with classical risk
factors and paternal age at birth
Telomere length was not significantly correlated with age (r=
0.01, p=0.79) and this was probably due to the very narrow
age range (18–28 yrs) of the present young cohort. There
was a weak but significant positive correlation of telomere
length with HDL cholesterol (r=0.10, p=0.005) and glucose
(r=0.21, p=0.0001) levels and also weak but significant
negative correlation with waist/hip ratio (r=−0.09, p=0.02),
apo B (r=−0.11, p=0.003), apo E (r=−0.21, p<0.0001),and
homocysteine concentration (r=−0.10, p=0.01), after adjust-
ment for age, region and case–control status (Table 3). These
correlations, apart from the ones with glucose and apo E,
were not consistent in cases and controls, although for all of
them the test of homogeneity for the effect in cases and
controls was not significant. When adjusted for HDL,
glucose, waist/hip ratio, apo B, apo E, and homocysteine
levels the association between length and case–control status
remained highly significant in the Baltic and non-significant
in the other regions. The significance in the geographical
differences did not change after these adjustments. No
significant association of telomere length with smoking,
alcohol consumption, or physical activity was found in cases,
controls, or the combined cohort (data not shown).
According to previous studies [20], paternal age at birth
may have an effect on the child's telomere length. The
paternal age at birth was calculated from the age of the
offspring and the fathers' age at recruitment in the control
group. We found no significant correlation between father's
age at birth and child's telomere length (r=0.02, p=0.08,
Table 3). Such data were insufficient for the cases, since
one third of their fathers had already died at the time of
recruitment.
Discussion
In this study, we report a borderline significant association
of shorter leukocyte telomere length and paternal history of
premature MI in a large multicenter European study and a
highly significant association in the Baltic region. Specif-
ically, we found that overall the offspring of premature
CHD patients had on average ∼550 bp shorter telomeres
than individuals of the same age free of paternal history.
This difference is greater than the ∼300 bp difference
between coronary artery disease patients and controls of
42–72 years of age, reported by Samani et al. [2], or the
∼300 bp difference between MI patients and controls of 40–
53 years of age, reported by Brouillete et al. [8]. Although,
the effect is of modest statistical significance, it is likely
that the true size of the effect is larger when taking into
account that the present cohort consists of young healthy
men of a very narrow age range (18 to 28 years) having just
Table 2 Geometric mean (95% CI) of telomere length (T/S ratio) in cases and control across Europe
Mean (95% CI) T/S ratio
in the combined cohort
Mean (95% CI) T/S
ratio in cases
Mean (95% CI) T/S
ratio in controls
p value for the
case–control difference
Overall (369 cases/396 controls) 1.38 (1.31–1.44) 1.30 (1.22–1.39) 1.42 (1.34–1.52) 0.05
Baltic (85 cases/88 controls) 1.18 (1.08–1.30) 0.96 (0.84–1.09) 1.45 (1.27–1.65) <0.0001
UK (69 cases/81 controls) 1.55 (1.39–1.72) 1.64 (1.41–1.91) 1.48 (1.29–1.71) 0.27
Middle (121 cases/122 controls) 1.69 (1.56–1.84) 1.68 (1.49–1.88) 1.71 (1.53–1.92) 0.82
South (94 cases/105 controls) 1.11 (1.02–1.21) 1.10 (0.97–1.24) 1.13 (1.00–1.27) 0.78
Mean T/S ratio for the combined cohort in each region was adjusted for age and paternal history. p value for the difference in mean telomere
length across regions, p<0.0001. Mean T/S ratio in cases and controls were adjusted for age in each region, and further adjusted for region for the
overall results. Tests of homogeneity for the case–control differences among regions, p<0.001.
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trols. Moreover, the effect observed here is diluted since
only half the genetic information of an offspring is inherited
from the CHD prone father with the mother's non-risk
telomeres contributing to 50% of the measured length.
The present data compose the first documentation of a
geographical diversity in telomere length across Europe.
Students from the Baltic countries and the South of Europe
had shorter telomeres (∼7.94 kb and ∼7.62 kb respectively)
while students from the Middle of Europe had the longest
Fig. 2 Distribution of telomere length in each European region for the cases and the controls
Fig. 1 Distribution of telomere
length in each European region
for the combined cohort
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history also displayed a geographical diversity. Young men
from the Baltic countries whose fathers suffered an early
MI had ∼2.24 kb shorter telomeres than men of the same
age free of paternal history. This difference was highly
significant, while this was not the case for the other regions.
The strong association seen in the Baltic can not be
attributed to particularly short mean length in that region,
since the length was as short in the South, but rather to
greater differences between cases and controls. A possible
explanation of this discrepancy could be that the Baltic
population differs genetically from the rest of Europeans. In
support of this, the frequency of various genetic polymor-
phisms (e.g., PPARγ Pro12Ala, MTHFR C677T, lipoprotein
lipase gene (LPL) HindIII, LPL S447X) is also different in
the Baltic compared to the rest of Europe [21–23].
Family history of premature CHD is a well-established
independent risk factor for CHD [24, 25]. This study was
undertaken to determine to what extent telomere length
contributes to the family history-associated risk and its
relationship with other risk factors. Data from other studies
suggest an accelerated telomere shortening related to
obesity, smoking and presence of type 1 and 2 diabetes,
probably mediated through the increased oxidative stress
caused by these factors [26–28]. In addition, pulse pressure
and pulse wave velocity have been associated with shorter
length [29]. Of the clinical, biochemical, and lifestyle risk
factors measured, HDL cholesterol and glucose were
positively correlated with the length, while waist/hip ratio,
apo B, apo E, and homocysteine displayed a negative
correlation. Though, all the correlations were weak and
apart from glucose and apo E, not consistent in cases and
controls. The correlation of apo E levels with telomere
length has not been observed before, and despite being
weak could account in part for the geographical diversity
seen in length, since its levels differ across the European
regions. However, the apo E levels display an increasing
north-to-south gradient, while the length was as short in the
Baltic as in the South of Europe. Homocysteine on the
other hand, also exhibits regional differences and has been
found to increase the amount of telomere length lost per
population doubling in endothelial cells through a redox-
dependent pathway [30]. However, its levels were highest
in the South [22] which again is not in accordance with the
geographical differences seen in telomere length.
The young age of this cohort may be the reason for the
risk factors not to have exerted a large effect on telomere
length. This implies that at this early age the inter-
individual differences in length are more likely to be
genetically than environmentally determined. More impor-
tantly, the association of short telomeres and paternal
history did not change appreciably after adjusting for
w a i s t / h i pr a t i o ,H D L ,a p oB ,a p oE ,g l u c o s e ,a n d
homocysteine levels, indicating that it is not mediated by
them. Nevertheless, while the environment may not yet
have affected telomere length in the young offspring, it
could have played a role in the fathers' early CHD onset.
This might explain the strong association of short length
with paternal history of early CHD seen in the Baltic and
not in the rest of Europe. Another factor which was shown
Table 3 Partial Pearson correlation coefficients of telomere length (T/S ratio) with classical risk factors
Risk factors r in cases p value r in controls p value r in cases and controls pooled p value
Age (yrs) 0.10 0.06 −0.07 0.14 0.01 0.79
BMI (kg/m
2) −0.12 0.02 −0.02 0.69 −0.07 0.05
Waist/hip ratio -0.08 0.12 −0.11 0.04 −0.09 0.02
SBP (mmHg) 0.09 0.11 0.04 0.45 0.06 0.12
DBP (mmHg) −0.03 0.60 −0.03 0.59 −0.04 0.30
Total cholesterol (mmol/l) −0.07 0.17 −0.04 0.48 −0.05 0.19
LDL cholesterol (mmol/l) −0.10 0.07 −0.05 0.34 −0.07 0.07
HDL cholesterol (mmol/l) 0.16 0.003 0.05 0.30 0.10 0.005
Apo B (mg/dl) −0.15 0.004 −0.08 0.13 −0.11 0.003
Apo A1 (mg/dl) 0.06 0.23 0.03 0.55 0.05 0.15
Apo E (mg/dl) –0.22 <0.0001 −0.21 <0.0001 −0.21 <0.0001
Triglycerides (mmol/l) −0.08 0.16 −0.03 0.62 −0.05 0.19
Glucose (mmol/l) 0.26 <0.0001 0.18 0.0004 0.21 <0.0001
Insulin (mU/l) −0.07 0.17 0.06 0.29 −0.02 0.66
Homocysteine (μmol/l) −0.15 0.007 −0.04 0.40 −0.10 0.01
Pearson partial correlation coefficient r was adjusted for age and region and further adjusted for case–control status when cases and controls are
pooled. Tests of homogeneity of the association of telomere length with waist/hip ratio, HDL cholesterol, apo B, apo E, glucose and homocysteine
between cases and controls were non-significant.
BMI Body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HDL high density lipoprotein, Apo apolipoprotein, LDL low-
density lipoprotein
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telomere length is paternal age at birth. No such association
was observed in this study even though the paternal age
range was relatively wide (31±12 yrs).
So far, the influence of CHD paternal history in the
EARS I and II studies was mainly expressed in terms of
differences in biochemical measurements (i.e., fasting or
postprandial triglycerides, total cholesterol and apo B
levels) [31–33]. Here, we show a potential biomarker
attributing to the family history-related risk independently
of biochemical or lifestyle factors. In addition, most
candidate gene studies with the EARS II sample, apart
from the HindIII and S447X variants in the lipoprotein
lipase gene, found no differences in genotype frequencies
between cases and controls [21–23, 31]. Thus, telomere
length offers a novel insight into the genetic basis of family
history, constituting a possible inherited and early
expressed risk factor for CHD.
In vivo experiments have shown a progressive telomere
shortening in vascular regions susceptible to atherosclerosis
[34], while in vitro experiments have provided data for the
contribution of endothelial cell senescence, induced by
telomere shortening, in atherogenesis [6]. This suggests a
plausible mechanism for the role of telomere shortening as
a primary abnormality in the development of CHD.
Atherosclerosis is also accompanied by systemic inflam-
mation and thus marked increased cell turnover, which
results in shorter leukocyte telomere length [7]. This offers
another possible explanation for the short telomere length
in leukocytes of individuals prone to CHD. However, the
outcome of the present study, coupled with that of twin
studies showing that epigenetic/environmental effects on
length are relatively minor during life [15], support the
theory that in individuals born with relatively short
telomeres, vascular cells will reach senescence faster and
they will develop atherosclerosis in an earlier age than
others.
Limitations of our study need to be considered. The
possibility that an unmeasured factor such as inflammation
could account for the observed association of telomere
length with paternal history of MI cannot be excluded.
Although other studies have used leukocyte DNA to
examine the relationship of telomere length with CHD risk
[2, 8, 9], telomeres display tissue-specific lengths and rates
of loss, so it is not firmly established whether inter-
individual differences seen in leukocyte telomere length
apply to other cell types and especially the vascular tissue.
However it is clear that, in comparison to other persons,
these who exhibit relatively short or long length in one type
of a proliferative somatic cell, respectively express rela-
tively short or long telomeres in other somatic cells [35]. A
possibility of a certain degree of degradation due to storage
of the leukocyte DNA for a long period of time should be
considered, although telomeres are rather stable complexes
of GC-rich double stranded DNA and should maintain their
structure when diluted DNA is frozen. The evaluation of
telomere length in leukocyte DNA samples stored for as
long has been previously preformed in the WOSCOP study
[9]. The telomere sizes reported there were lower in average
than that in EARS II, as would be expected due to the
different mean age of the study cohorts and validation of
the assay between these two studies allows the comparison
to be made.
To summarize, the data suggest that, in young men, the
biological expression of a paternal history of premature
CHD primarily in the Baltic is at least in part mediated
through inherited short telomeres, independently of the
risk factors examined in this study. Whether telomere
length is only serving as a biomarker of CHD risk, or if it
has a functional basis remains to be determined. Results
from large prospective studies with follow-up measure-
ments of telomere length will have the possibility to
ascertain if individuals with a genetic tendency to
relatively short telomeres in leukocytes are at higher risk
for developing premature CHD independently of conven-
tional risk factors.
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